Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
MISSISSAUGA, Ontario, May 15, 2017 /CNW/ -- Profound Medical Corp. (OTCQX: PRFMF) (TSX-V: PRN), based in Ontario, an emerging medical device company focused on prostate care, today announced that the May 11 presentation from CEO, Arun Menawat, is now available for on-demand viewing at VirtualInvestorConferences.com.
Profound Medical Corp.'s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
- Profound Medical Corp. announced its common shares are available for trading on the OTCQX® Best Mark starting March 13, 2017
- Profound Medical Corp. announced on April 18th it secured Depository Trust Company (DTC) eligibility for its shares traded on the OTCQX market.
About Profound Medical Corp.
The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. For the millions of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate cancerous prostate tissue with precision, while actively protecting critical anatomy from potential side effects; a tomorrow where patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.
Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO™, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO™ is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Profound Medical Corp.
For further information: Profound Medical Corp., Stephen Kilmer, Investor Relations, email@example.com, T: 647.872.4849; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, firstname.lastname@example.org